恶性黑色素瘤患者免疫反应相关的基因组变化
Linqing Li1, Tianmin Xiang2, Xianan Li1
1Department of Orthopedics, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan, China.
Medicine
|April 26, 2024
概括
在晚期黑色素瘤中,免疫检查点抑制剂 (ICI) 的预测生物标志物至关重要. 基因组分析确定了特定的基因突变,如FAT1和ATM,作为ICI治疗对持久临床益处的潜在指标.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫检查点抑制剂 (ICI) 提高了晚期黑色素瘤的存活率.
- 患者对ICI的反应有所不同,需要预测生物标志物.
- 瘤基因组分析可能会提高治疗预测.
研究的目的:
- 调查瘤基因组分析是否预测黑色素瘤患者ICI的临床益处.
- 为了确定与治疗反应相关的特定基因突变.
主要方法:
- 综合下一代测序 (NGS) 数据具有临床病理学特征.
- 分析了突变特征,包括BRAF/RAS/NF1状态和突变特征.
- 相关的基因突变和PD-L1表达与无进展生存 (PFS) 和持久的临床益处 (DCB).
主要成果:
- 鉴定出已知免疫治疗相关的基因,具有高突变频率.
- 发现43.2%的患者有BRAF/RAS/NF1突变;56.8%是三重WT.
- 观察到突变特征6 (DNA不匹配修复缺陷).
- 较高的PD-L1表达 (≥1%) 与改善的PFS相关,但不是DCB.
- 在DCB患者中,FAT1,ATM,BRCA2,LRP1B和PBRM1突变是常见的,独立于PD-L1状态.
结论:
- 瘤基因组分析为黑色素瘤患者对ICI的反应提供了洞察力.
- 特定的基因突变 (FAT1,ATM,BRCA2,LRP1B,PBRM1) 可能作为ICI疗效的预测生物标志物.
- 对这些分子特征的进一步研究可以指导个性化的黑色素瘤治疗策略.
相关概念视频
01:27Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
01:30Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:21Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K